A drug company has announced a partnership with a cannabis producer to bring a novel transdermal and intranasal delivery system for medical cannabis.

NanoSphere Health Sciences (CSE:NSHS) has entered an initial agreement through which it will hand Delta 9 Cannabis (TSXV:NINE) the exclusive master license for its patented NanoSphere Delivery System for all of Canada.

David Sutton, president and chief operating officer of NanoSphere, told the Investing News Network (INN) that if completed, the memorandum of understanding between NanoSphere and Delta 9 will be key in getting the delivery system approved by Health Canada.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

“[Delta 9] has a good relationship with Health Canada, and our product in its current form wouldn’t be sellable without Health Canada’s approval,” David Sutton said. “We really feel that they have the ability to help get that through that process.”

David Sutton said he expects the application process for the drug delivery method with Health Canada to begin even before the deal between the two companies is finalized. When asked when he expects it to receive approval, the executive told INN he couldn’t say.

“Dealing with government bodies is an unknown environment,” he said.

According to the announcement from the two companies, Delta 9 and NanoSphere will get a 50-percent split of net revenue from eventual sales of the product, sold as the Evolve Formulas brand.

The US-patented delivery system transports the drug through the skin into the bloodstream. The company cites cannabis applications in which patients can obtain “transdermal viscous gels, intranasal products and intraoral products.”

David Sutton explained this process removes the smoking element from medical cannabis and is more effective in treating pain since the delivery method encapsulates THC molecules, allowing safe transport through the skin.

“We hope through our work to eliminate the need for patients to be essentially ‘smoking their medicine,’ and to give physicians a new and important tool to treat conditions that respond to cannabinoids,” said Robert Sutton, CEO of NanoSphere.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

Delta 9 will get access to the IP of NanoSphere and will receive training on how to use the delivery system with medical cannabis.

“The lack of a standardized delivery system has been the single greatest impediment for doctors who would otherwise prescribe cannabis for various medical conditions,” John Arbuthnot, CEO of Delta 9 said. Arbuthnot added that the company has not seen anything resembling NanoSphere’s delivery in terms of “safety and precision of dosage.”

Benefits of NanoSphere’s drug delivery system with cannabis

David Sutton told INN the formula for the Evolve Formulas products was perfected by NanoSphere after a variety of trials. The formulas are dispensed through a pen-like device in which the user pushes a button to receive the medicine.

Each push of the button dispenses 125 microliters of material that has 5 milligrams of THC and 2 milligrams of cannabidiol (CBD) and 2 milligrams of tetrahydrocannabinolic acid (THCA).

Investor takeaway

Since the partnership was revealed last Tuesday (July 31), Delta 9’s share price has spiked 9.17 percent, reaching a closing price of C$1.32 on Wednesday (August 8). On the other hand, NanoSphere’s share price has declined 2.44 percent since the announcement and closed at a price of C$0.40 during Wednesdays’ trading session.

As cannabis and its use as a medicine become more relevant in Canada, a variety of novel products and methods will begin making their entry into the market.

This partnership shows a drug company with an interest in cannabis aligning itself with a producer that has built a relationship with Health Canada.

Don’t forget to follow us @INN_Cannabis for real-time news updates! 

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
  • Company has received UK Continuing Professional Development (“CPD”) accreditation for its global education platform, Khiron Academy
  • UK medical professionals may now earn CPD credits through Khiron’s medical cannabis education program
  • The Company has entered into a strategic partnership with Cellen Therapeutics, a leader in digital healthcare in the UK, to increase patient access via medical cannabis education
  • As a leading international medical cannabis educator, nearly 1,000 medical professionals in Latin America and the United Kingdom have registered for, or completed, Khiron Academy training

 Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN) (OTCQX: KHRNF) ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe is pleased to announce it has received UK Continuing Professional Development (“CPD”) accreditation for Khiron Academy, the Company’s global medical cannabis education platform.

Additionally, following its accreditation, the Company has entered into a strategic partnership with Cellen Therapeutics, a leader in digital healthcare in the UK and fellow founding member of Project Twenty21, to increase patient access through medical cannabis education initially. Khiron Academy will be made available to prescribers in the UK that have registered with Cellen’s MedCanHub, an emerging education portal. Cellen is market leader, widely recognized for also launching the UK’s first digital pain clinic, Leva.

Keep reading... Show less

TRACE’s plant-based and alkaline wellness products to expand into key markets of Japan, China and the Philippines

Emerging leader in innovative health and wellness beverages and consumer products, BevCanna Enterprises Inc . ( CSE:BEV , Q:BVNNF , FSE:7BC ) (“ BevCanna ” or the “ Company ”) announces today its anticipated expansion into the Asia Pacific region, through its wholly-owned subsidiary Naturo Group. After completing a comprehensive market, distribution and partner assessment, the Company intends to initially launch its portfolio of TRACE health and wellness products in the key markets of Japan, China, and the Philippines, through multi-channel distribution outlets including e-commerce, retail, and wholesale.

Keep reading... Show less

Trulieve acquires dispensary permits from Solevo Wellness West Virginia LLC for $650,000

Trulieve Cannabis Corp . (CSE: TRUL) (OTCQX: TCNNF), a leading and top-performing cannabis company in the United States and the largest cannabis company in Florida announced today that it acquired Solevo Wellness West Virginia LLC (“Solevo”) and its three West Virginia dispensary permits for $650,000 . Solevo was awarded two permits in Morgantown and one in Parkersburg in January 2021 as part of the West Virginia application process.

Keep reading... Show less

Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) a wellness company that develops and sells sustainable, plant-based products, is pleased to announce that it’s Jusu Home and Body line is now available for purchase on Faire Wholesale Marketplace (“Faire” or “www.faire.com”), an online wholesale marketplace valued at US $2.5 billion. Jusu Home and Body products are currently featured in their “New Arrivals” section.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6377/80230_8c77c54544bf884c_001.jpg

Keep reading... Show less

 Aion Therapeutic Inc. (CSE: AION) (” Aion Therapeutic ” or the ” Company “) today announced that it has retained KCSA Strategic Communications (” KCSA “), a leading New York City -based communications firm.

Keep reading... Show less